The latest research progress and future clinical application prospects of Pimitespib

Pimitespib is an oral heat shock protein 90 (HSP90) inhibitor, mainly used for the treatment of advanced gastrointestinal stromal tumors (GIST). HSP90 plays a role in stabilizing a variety of oncogenic proteins in tumor cells, such as KIT and PDGFRA. By inhibiting HSP90, pimetibi can promote the degradation of these oncogenic proteins, inhibit tumor proliferation and survival, and thus exert anti-tumor effects. This mechanism of action makes it still potentially effective in patients with TKI-resistant GIST, providing a new option in addition to traditional targeted therapy.

In the CHAPTER-GIST-301 clinical trial, pimotebi was used in patients with advanced GIST who were resistant to multiple lines of therapy. The results of the study showed that pimetibib significantly prolonged the progression-free survival (PFS). The median PFS was about 2.8 months, while the placebo group was 1.4 months. The efficacy was significantly better than the control group. In addition, the drug was generally well tolerated and no serious uncontrollable adverse events occurred, providing patients with a new treatment option.

Currently, pimetibib is also exploring the possibility of being used in combination with other anti-cancer drugs. For example, an ongoing Phase I clinical trial is evaluating its combination with imatinib in patients with advanced imatinib-resistant GIST; another Phase II trial is studying its combination with enzalutamide in castration-resistant prostate cancer. These studies show that pimetibib can not only be used alone, but may also enhance its efficacy through combination therapy and expand its application potential in other solid tumors.

As the first approved HSP90 inhibitor, pimetibi has shown unique value in TKI-resistant patients and filled the treatment gap. In the future, its expansion of indications in other solid tumors is worth looking forward to. However, potential side effects such as eye reactions and gastrointestinal discomfort still need to be paid attention to, and the long-term efficacy and safety in different populations still need to be further verified. With the release of more clinical study results, pimetibi is expected to become an important treatment option for a variety of refractory tumors.

Reference materials:https://www.drugs.com/